跳转至内容
Merck
CN

Y0001295

螺内酯

European Pharmacopoeia (EP) Reference Standard

别名:

4-孕烷-21-油酸-17α-醇-3-酮-7α-硫醇γ-内酯7-乙酸盐, 7α-(乙酰硫基)-17α-羟基-3-氧杂戊烯-4-烯-21-羧酸γ-内酯

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H32O4S
CAS号:
分子量:
416.57
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

spironolactone

制造商/商品名称

EDQM

mp

207-208 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChI key

LXMSZDCAJNLERA-ZHYRCANASA-N

基因信息

human ... NR3C2(4306)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Spironolactone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

螺内酯是竞争性醛固酮受体拮抗剂。 用作保钾利尿剂。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Carc. 2 - Repr. 1B - STOT RE 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
Andrew S Bomback et al.
Nature clinical practice. Nephrology, 5(2), 74-75 (2008-11-26)
Natalie A Christy et al.
The Annals of pharmacotherapy, 39(9), 1517-1521 (2005-08-04)
To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone. Studies and reports were located in MEDLINE (1966-January 2005), EMBASE, and International Pharmaceutical Abstracts through the second week of January 2005. Hirsutism
Julie Brown et al.
The Cochrane database of systematic reviews, (2)(2), CD000194-CD000194 (2009-04-17)
Hirsutism is the presence of excessive hair growth in women and is an important cosmetic condition often resulting in severe distress. The most common cause is by increased production of male sex hormones (androgens). It is also affected by increased
Cristián A Amador et al.
Hypertension (Dallas, Tex. : 1979), 63(4), 797-803 (2014-01-15)
Adaptive immune response has been implicated in inflammation and fibrosis as a result of exposure to mineralocorticoids and a high-salt diet. We hypothesized that in mineralocorticoid-salt-induced hypertension, activation of the mineralocorticoid receptor alters the T-helper 17 lymphocyte (Th17)/regulatory T-lymphocyte/interleukin-17 (IL-17)
Joel C Marrs
The Annals of pharmacotherapy, 44(11), 1762-1769 (2010-10-28)
To review the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and adverse effects of spironolactone in the treatment of resistant hypertension. A literature search was conducted using MEDLINE (1966-July 2010), International Pharmaceutical Abstracts (1970-July 2010), and Cochrane database (2009) for the key

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门